Abstract

Reducing the burden of long-term complications in type 2 diabetic patients remains a major task, and represents a huge challenge. Whilst tight glycemic control has been shown to reduce the risk of microvascular complications, controversy remains regarding the benefit of intensive treatment in relation to the prevention of cardiovascular events. Recent large trials (including ACCORD, ADVANCE, and VADT) were unable to show a significant impact of glycemic control on cardiovascular events. Also, it has been argued that these trials included patients with a long duration of the disease, and with previous unsatisfactory glycemic control. Chronic exposure to hyperglycemia may cause a kind of negative metabolic memory, and thereby reduce the potential impact of good glycemic control. This concept has been corroborated by the UKPDS which recruited only subjects with newly diagnosed diabetes and without prior cardiovascular events. In these patients, early achievement of glycemic control translated into a long-term reduction of the risk of micro- and macrovascular complications. This observation prompted the UKPDS investigators to propose a positive “glycemic legacy”, supporting the need for early and appropriate treatment of hyperglycemia and associated metabolic disturbances. This should be feasible now through the selection of individual targets and personalized pharmacologic treatments. In doing so, the potential risks of intensive treatment might then be avoided.

Keywords: antihyperglycemic therapy · cardiovascular risk · glycemic control · glycemic legacy · macrovascular · microvascular complication · type 2 diabetes · UKPDS

Introduction

A recent analysis published by Danaei et al. has revealed an even more dramatic picture of the ongoing “epidemic” of diabetes across the world than was once foreseen [1]. In the 10 world regions examined, the prevalence of diabetes has been steadily increasing in both genders during the period 1980-2008. The overall figure shows that in 1980, the global diabetic population was 153 million. This figure has more than doubled since 2008, reaching the extraordinary number of 357 million. If growth continues at the same rate, then future humanity will be facing an even greater societal and economical problem than at present. The conclusion of the paper by Danaei et al. was very straightforward. The authors observed that “effective preventive interventions are needed, and health systems should prepare to detect and manage diabetes and its sequelae” [1]. Indeed, the major burden of diabetes originates from the elevated risk of its dreadful complications, and its sequelae. Among people with diabetes, the prevalence of complications remains unac-
ceptably high. Deshpande et al. have recently reported that up to 30% of the diabetic population have some microvascular complications, and at least 10% already have had a cardiovascular (CV) event [2]. Applying these proportions to the figures from Danai et al., we can estimate that approximately 110 million diabetic patients will have microvascular complications, and 40 million will experience CV events.

Multiple factors contribute to CV risk in diabetes. However, hyperglycemia, the hallmark of the disease, constitutes a powerful capacity to predict mortality even in the general population. The Emerging Risk Factors Collaboration has clearly indicated how increased plasma glucose levels are associated with a significant increase in the risk of mortality in different diseases, including cancer and vascular disease, even in the non-diabetes population [3] (Figure 1). The relationship is so strong that risk increases with the elevation of plasma glucose in an almost linear fashion. When looking at this relationship, one could argue that lowering plasma glucose levels towards the normal range should be associated with reduction of risk for morbidity and mortality of all causes. Although this concept appears intuitive, conclusive proof does not emerge from the results of the most recent intervention trials.

**Intervention trials in diabetes**

The United Kingdom Prospective Diabetes Study (UKPDS) was the first trial to provide strong evidence that appropriate glycemic control could lead to a significant reduction of the risk for long-term diabetic complications [4]. The trial recruited 3,867 newly diagnosed type 2 diabetes (T2D) patients who were randomly assigned to intensive treatment with a sulfonylurea or insulin, or to conventional management, mainly based on diet [4]. Over the 10-year follow-up, average hemoglobin A1c (HbA1c) was 7.0% in the intensive-treatment group compared with 7.9% in the conventional group. Compared with the latter, the risk of developing diabetes complications in the intensive-treatment group was reduced by 12% (95% confidence interval (CI) 1-21, p = 0.029) for any diabetes-related endpoint, 10% (95% CI 11-27, p = 0.34) for any diabetes-related death, and 6% (95% CI 10-20, p = 0.44) for all causes of mortality. In the diabetes-related aggregate endpoint, the risk reduction in microvascular complications amounted to 25% (95% CI 7-40, p = 0.0099). Also, a 16% reduction in the risk of myocardial infarction was reported, although this was only close to statistical significance (p = 0.052). This finding led to much discussion, and left the question unresolved whether glycemic control may contribute to a reduction of the CV risk in diabetes.

The issue was not solved by the results in the Kumamoto study [5]. In this trial, a small number of Japanese patients on intensive insulin treatment achieved much better glycemic control (HbA1c 7.1% vs. 9.45%) than those on conventional insulin therapy. In the intensively treated patients, the cumulative percentages of the development and progression in retinopathy, nephropathy, and neuropathy were significantly lower. After 8-year follow-up, there was also an apparent positive effect on macrovascular complication, as indicated by an almost 50% reduction in the number of CV events in intensively vs. conventionally treated subjects. Unfortunately, the absolute number of events was too small to allow formal statistical analysis, so that no final conclusion could be drawn.

Five thousand and thirty-eight T2D patients with evidence of macrovascular disease were recruited in the PROactive trial [6]. The patients were randomly assigned to receiving oral pioglitazone, or placebo, added to any existing glucose-lowering medication. During the 34.5-months of observation, there was no significant reduction in the primary CV endpoint with pioglitazone (hazard ratio (HR) 0.90, 95% CI 0.80-1.02, p = 0.095). Whereas, a statistical significance was achieved for the pre-defined secondary endpoint, i.e. a composite of all-cause mortality, non-fatal myocardial infarction, and stroke (HR 0.84, 95% CI 0.72-0.98,

**Abbreviations:**

ABCD - age, body weight, complications, diabetes duration  
ACCORD - Action to Control Cardiovascular Risk in Diabetes (trial)  
ADA - American Diabetes Association  
ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation  
AGE - advanced glycation end-product  
AHA - American Heart Association  
CI - confidence interval  
CV - cardiovascular  
EASD - European Association for the Study of Diabetes  
FPG - fasting plasma glucose  
Hba1c - glycated hemoglobin A1c  
HR - hazard ratio  
LDL - low-density lipoprotein  
PKC - protein kinase C  
RR - relative risk  
T2D - type 2 diabetes  
UKPDS - UK Prospective Diabetes Study  
VADT - Veteran Affairs Diabetes Trial
p = 0.027). In summary, the PROactive trial could not prove beyond all reasonable doubt, that intensive glycemic control provides a solid benefit with respect to prevention, or reduction, in CV risk in T2D patients.

More recently, the results of three large intervention trials [7-9], enrolling a total of 23,000 T2D patients, revived the debate on the relationship between glycemic control and CV outcomes. In the ADVANCE study (Action in Diabetes and Vascular Disease: Preterax and Diamicon Modified Release Controlled Evaluation), a lower mean HbA1c level was achieved in the intensive-control group than in the standard-control group (6.6 vs. 7.3%) [7]. Intensive control reduced the incidence of combined major macro- and microvascular events (HR 0.90, 95% CI 0.82-0.98, p = 0.01), and major microvascular events (HR 0.86, 95% CI 0.77-0.97, p = 0.01). In contrast, there was no significant effect from glucose control on major macrovascular events, death from CV causes, or death from any cause. In the Veteran Administration Diabetes Trial (VADT) [8], median HbA1c levels were 8.4% in the standard-therapy group, and 6.9% in the intensive-therapy group. There was no significant difference between the two groups in the rate of CV events, or in the rate of death from any cause (HR 1.07, 95% CI 0.81-1.42, p = 0.62). Likewise, no differences between the two groups were observed for microvascular complications, with the exception of reduced progression of diabetic nephropathy. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study [9] was prematurely discontinued because of a 22% increased in risk mortality (95% CI 1.01-1.46) in the intensively treated group.

Interpreting the results of large clinical trials

Although the results of the recent large clinical trials sound clear-cut, it is worth critically analyzing their features [10]. The VADT, ACCORD, and ADVANCE studies included individuals at high CV risk. This is apparent from the high prevalence of patients with prior CV events (35%), and more than 50% having microvascular complications [8-10]. Because of the high CV risk, an aggressive treatment of CV risk factors was introduced to lower LDL-cholesterol (∼2.3 mmol/l) and blood pressure (∼120/70 mmHg). Also, antiplatelet therapy was used in 62-93% of the patients, and the number of people who were still smoking by the end of the study (8-17%) was reduced. Multifactor intervention has been already shown to be effective. Therefore, it is not surprising that the mortality rate (∼2.2% per year) in the trials was as low as in the general population. Under these conditions, it is difficult to demonstrate the benefits of tight glycemic control.

On the other hand, when patients without a prior CV event were evaluated, tight glycemic control was associated with a significant reduction of primary CV outcomes. A similar reduction could be observed in patients with HbA1c ≤ 8.0% at study entry, as compared with those with values ≥ 8.0%. One may assume that the lack of prior CV events, or microvascular complications, and a lower baseline HbA1c may reflect a shorter duration of the disease, and an overall better health status. Thus, duration of diabetes and prior CV events may be the key factors influencing the results of these recent trials, where strict glycemic control was achieved only after years of uncontrolled diabetes [10]. Ideal conditions for good glycemic control and health status prevail when diagnosis is made early and glycemic control is ensured from the time of diagnosis.

The difference between the ideal approach and what happens in the trials is graphically illustrated in Figure 2. It can easily be seen how this difference can i) lead to the development of diabetic complications, or ii) generate a "bad glycemic legacy". The latter relates to the "legacy effect", which was proposed from the post-trial results of UKPDS [11]; intensive treatment implemented at

![Figure 1. Hazard ratios for major causes of death. Diabetes vs. non-diabetes [1].](image-url)
the time of diagnosis results in a sustained reduction in the risk of micro- and macrovascular complications. In the 10-year post-trial follow-up, patients originally randomized to intensive treatment maintained significant reductions in the rates of diabetes-related endpoints and microvascular complications. Also, they had a significant reduction in the risk of myocardial infarction (relative risk (RR) reduction of 15%, \( p = 0.0014 \)) and all-cause mortality (RR reduction 13%, \( p = 0.007 \)) [11]. These results were obtained although there were no longer differences in HbA1c values between patients originally assigned to conventional treatment, and those of the intensive-treatment group. Therefore, it was concluded that the legacy of good glycemic control in the initial stages of T2D translated into a permanent benefit related to micro- and macrovascular risk factors.

The relationship between diabetes duration before initiating intensive treatment and outcome is illustrated in Figure 3. The longer the duration, the smaller is the effect of tight glycemic control on diabetic complication. This view should lead to a change in the treatment of T2D, starting with implementation of appropriate treatment at the time of diagnosis, and leading to a reduction in treatment-associated risk for those patients with long disease duration. Early intervention is safer, and more effective, because of the probability of diabetic complications at diagnosis being relatively low. In this case, the “glycemic legacy” is of short duration, and is easier to modify. In these patients, targeting normoglycemia is feasible and necessary. In all cases, an uncompromised therapeutic approach should be applied, including the treatment of all CV risk factors.

The results from the extended phase of the STENO-2 trial provide compelling evidence that effective management of hyperglycemia, elevated blood pressure, and lipid disorders has beneficial health effects [12]. The study showed that, despite the lack of significant differences in cardio-metabolic risk factors, including HbA1c, systolic and diastolic pressure, triglyceride, total cholesterol and LDL-cholesterol levels, a substantial difference in the incidence of defined endpoints was maintained over many years. The outcomes were much better in the intensive treatment group. These findings support the positive role of a “metabolic legacy”, rather than simply a “glycemic legacy”.

In summary, the UKPDS and STENO-2 studies provided evidence that intensive treatment of chronic hyperglycemia, and related metabolic abnormalities, in early stages of the disease, yield beneficial outcomes with long-term effect [11, 12]. In contrast, a delay in effective treatment of metabolic disturbances can cause a spectrum of adverse biological reactions in vascular endothelial cells that may become irreversible. Preliminary work in endothelial cells has shown that hyperglycemia can induce changes in gene expression depending on modifications of histone tails (for instance, methylation). These changes persist, even after restoration of normoglycemia [13]. How these modifications persist over time is not clear. Epigenetic changes and biochemical processes (for example, advanced glycation) may contribute to the phenomenon, most likely as a consequence of sustained oxidative stress [14-16]. Excessive occurrence of free radicals triggers multiple intracellular pathways, including the activation of protein kinase C (PKC), increased fluxes through the polyol and hexamine pathways, and increased advanced glycation end-product (AGE) formation. Free radicals can also affect the expression of a number of genes involved in the pathogenesis of
The concept of the “vulnerable T2D patient” has been supported by a recent post-hoc analysis of the ACCORD trial, showing that the relationship between average HbA1c and mortality differs from that observed in other trials.

Phenotyping patients to reduce the risk

A more recent post-hoc analysis of the ACCORD study concluded that intensive therapy delayed the onset of albuminuria. Also, some measures of eye complications and neuropathy suggested a potentially positive effect of glycemic control on microvascular complications [20]. However, the investigators suggested to weigh the advantages against the risks, including increased total and CV related mortality, increased weight gain, and risk for severe hypoglycemia. The trial was stopped earlier than planned because of a markedly increased death rate, with 52 more deaths among patients in the intensive treatment cohort.

In summary, tight glycemic control can exert a protective effect to prevent or minimize microvascular complications. However, for a beneficial effect on CV risk, intensive glycemic control needs to be implemented as soon as possible after the diagnosis of diabetes. This is an ambitious goal that requires appropriate intensive treatment. On the other hand, intensive glycemic control is challenging as it may inflict some undesired risks such as frequent hypoglycemia and increased mortality.

Table 1. Patient characteristics in large clinical diabetes trials. Compared with the pivotal United Kingdom Prospective Diabetes Study (UKPDS), which enrolled newly diagnosed patients, recent trials have enrolled high-risk patient populations characterized by a longer duration of disease, older age, and more severe hyperglycemia (i.e. higher HbA1c levels) at baseline [5-7].

<table>
<thead>
<tr>
<th>Duration of diabetes (yr)</th>
<th>0</th>
<th>8</th>
<th>10</th>
<th>11.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean baseline HbA1c (%)</td>
<td>7.1</td>
<td>7.5</td>
<td>8.3</td>
<td>9.4</td>
</tr>
<tr>
<td>Mean baseline FPG (mmol/l)</td>
<td>8.0</td>
<td>8.5</td>
<td>9.7</td>
<td>11.4</td>
</tr>
<tr>
<td>Mean age (yr)</td>
<td>53</td>
<td>66</td>
<td>62</td>
<td>60</td>
</tr>
<tr>
<td>Micro</td>
<td>↓</td>
<td>↓</td>
<td>=↓</td>
<td>=</td>
</tr>
<tr>
<td>Macro</td>
<td>↓</td>
<td>=</td>
<td>↑</td>
<td>=</td>
</tr>
</tbody>
</table>
HbA1c > 7.0%

- History of severe hypoglycemia
- Limited life expectancy
- Long-standiing diabetes
- Advanced micro- and macrovascular complications

HbA1c < 7.0%

- Short duration of diabetes
- Long life expectancy
- No significant cardiovascular disease

MAY GAIN ADDITIONAL MICROVASCULAR BENEFIT AS WELL AS MACROVASCULAR PROTECTION

Figure 4. Treatment goal personalization. Recommendations according to the American Diabetes Association and the American Heart Association [19].
significant CV disease, and absence or presence of modest signs of microvascular complications. In these individuals, tight glycemic control may provide additional microvascular benefit.

Preventing the development of microangiopathic complications can also contribute to reduced CV risk. Both micro- and macrovascular complications share common pathogenetic defects such as oxidative stress. Moreover, microangiopathy is a systemic process involving all tissues of the body including the microvasculature of the heart. Such an involvement can contribute to an impaired outcome of atherogenic processes at the level of the coronary arteries, and contribute to the effect of traditional CV risk factors. In accordance with this hypothesis, diabetic retinopathy and other microvascular complications have been shown to be strong predictors of CV events [27].

Balancing risk and benefit of tight glycemic control

Glycemic control is recommended, but the expected benefits should be balanced against the potential risks which are associated with progressive but unsuccessful treatment intensity, such as severe hypoglycemia and body weight gain. In other words, the risk-to-benefit ratio must be determined individually, for each patient. This approach can only be processed by personalization of treatment goals and customized pharmacologic therapies.

Personalizing treatment may be rational, but it is not always a simple task, because concordant guidelines are lacking and physicians are not experienced with this method. A number of guidelines are available, but they tend to restrict rather than engage therapeutic options. To provide a user-friendly guideline for a personalized therapeutic approach for T2D patients, an independent university symposium was held at the EASD conference in Vienna, 2009. On this occasion, some elements were identified that may help to guide treatment selection. Also, the “A1C and ABCD of glycemia management in T2D” was proposed [28]. This method allows the individualization of the glycemic target based on age (A), body weight (B), complications (C), and duration of diabetes (D).

Age can be arbitrarily categorized as young (below 40), middle age, and elderly (>70). Individualized glycemic target and the speed of attainment of those targets can be selected based on this simple categorization (Figure 5). Body weight may help to guide initial pharmacologic intervention as body weight may reflect pronounced insulin resistance and differential CV risk profile. Complications should be evaluated in terms of increased CV and hypoglycemia risk and regarding treatment selection. Duration is likely to be linearly associated with the presence of co-morbidities and complications; it will require accurate fine-tuning in treatment to reduce the risk of severe hypoglycemia. In other words, drug selection and the HbA1c target should reflect the clinical status of the individual. Therefore, it is recommended that the pharmacological treatment in patients prone to hypoglycemia is carefully evaluated.

Most recently, Ismail-Beigi and coworkers proposed a more comprehensive view for the individualization of glycemic targets in T2D [29]. Choosing a specific HbA1c target range for a given patient requires that several factors are taken into consideration. These include an assessment of the patient’s risk for hyperglycemia-related complications versus the risks of therapy, co-morbid conditions, psychological status, capacity for self-care, economic considerations, family and social support systems.

Conclusions

We are convinced that the best interpretation of the recent intervention trials has been provided by one of the VADT principal investigators, who stated in the press conference: “If you go into a population that already has multiple risk factors, or prior CV disease, and long standing poor glu-
cose control, you cannot expect benefits from glu-
cose control in the short term. You can’t expect miracles!” Poor metabolic control leads to the de-
cesc control in the short term. You can’t expect benefits from glu-
cose and diabetes prevalence since 1980: systematic analysis
of health examination surveys and epidemiological studies
with 370 country-years and 2.7 million participants. Lanet 2011. 378:31-40.

2. Deshpande AD, Harris-Hayes M, Schootman M. Epi-


4. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk for complica-


Disclosures: SDP is member of the advisory panels of Novartis, Merck, Roche, Eli Lilly, Boehringer Ingelheim, Bristol-Myers Squibb, Astra Zeneca, GlaxoSmithKline, Sanofi, Takeda, and Novo Nordisk. He re-
ceived research support from Merck, Sanofi, and Ta-
keda.

References


4. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk for complica-


